Zura Bio (NASDAQ:ZURA) Shares Up 5.6% – Should You Buy?

Zura Bio Limited (NASDAQ:ZURA)’s stock price rose 5.6% during trading on Wednesday . The company traded as high as $5.46 and last traded at $5.3640. Approximately 121,596 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 843,188 shares. The stock had previously closed at $5.08.

Wall Street Analysts Forecast Growth

ZURA has been the topic of several research reports. Wedbush restated an “outperform” rating and set a $15.00 price objective on shares of Zura Bio in a research note on Wednesday, July 1st. Oppenheimer lowered their price target on Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research report on Monday. Chardan Capital raised their price objective on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Finally, William Blair assumed coverage on Zura Bio in a research note on Wednesday. They set an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Zura Bio presently has an average rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Stock Up 1.6%

The stock has a market cap of $489.58 million, a price-to-earnings ratio of -4.75 and a beta of -0.03. The firm’s 50 day moving average is $4.44 and its two-hundred day moving average is $5.32.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, analysts anticipate that Zura Bio Limited will post -0.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ZURA. Allworth Financial LP acquired a new stake in Zura Bio in the fourth quarter worth $30,000. Squarepoint Ops LLC grew its position in shares of Zura Bio by 34.6% during the fourth quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock worth $177,000 after acquiring an additional 8,680 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Zura Bio by 3.4% in the 1st quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock worth $1,864,000 after acquiring an additional 10,200 shares during the period. Finally, Scientech Research LLC bought a new stake in Zura Bio in the 3rd quarter valued at about $45,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.